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Available online 25 May 2016Age-related dysfunction ofmesenchymal stromal cells (MSCs) is suggested as amain cause of altered bone repair
with aging. We recently showed that in postmenopausal women undergoing cementless total hip arthroplasty
(THA) aging, low bone mineral density (BMD) and age-related geometric changes of the proximal femur are
risk factors for increased early migration and delayed osseointegration of the femoral stems. Extending these
analyses, we have here explored how the in vitro osteogenic capacity of bone marrow MSCs from these patients
reﬂects implant osseointegration, representing the patient's in vivo bone healing capacity. A total of 19 postmen-
opausal womenwith primary hip osteoarthritis (mean age 65 years, range 50–78) andwell-deﬁned bone quality
underwent successful preoperative in vitro analysis of osteogenic capacity of iliac crest bone marrow MSCs as
well as two-year radiostereometric (RSA) follow-up of femoral stemmigration after cementless THA. In patients
with MSCs of low osteogenic capacity, the magnitude of cumulative stem subsidence after the settling period of
three months was greater (p=0.028) and the time point for translational osseointegration was signiﬁcantly de-
layed (p=0.030) compared to patients with MSCs of high osteogenic capacity. This study suggests that patients
with MSCs of low in vitro osteogenic capacity may display increased stem subsidence after the settling period of
3 months and thereby delayed osseointegration. Our study presents a novel approach for studying the biological
progress of hip implant osseointegration and to verify the impact of decreased MSCs function, especially in pa-
tients with age-related dysfunction of MSCs and bone healing capacity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Age-related dysfunction of mesenchymal stromal cells (MSCs) is
emerging as the main cause of bone loss and altered repair capacity
with aging (Kassem and Marie, 2011; Baker et al., 2015). Decreased
MSC capacity with age is well documented in vitro, but it is unclear
how this reﬂects in vivo bone healing of the donors. As in any bone
healing process MSCs are essential in the progression of biological ﬁxa-
tion, osseointegration, of cementless total hip arthroplasty (THA). If ap-
propriate stem cells are not present, osteogenesis is inhibited (Kassem
and Marie, 2011; Pountos et al., 2013; Kienapfel et al., 1999).
Total hip arthroplasty is one of themost successfulmedical interven-
tions, recognized as an effective and reliable treatment for degenerative
joint disease. Millions of patients are being operated annually world-
wide, with a global trend over the last decade towards increased use
of cementless ﬁxation, representing the majority of THAs in North
America, Australia and several European countries (Troelsen et al.,nit, University of Turku/Turku
ritz@utu.ﬁ (N. Moritz),
. This is an open access article under2013; Lehil and Bozic, 2014). Cementless THA relies on biological ﬁxa-
tion of the implant to the surrounding bone, and is considered to take
about 3–6 months. Despite the high number of cementless stems im-
planted annually, very little is known about biological factors actually
affecting osseointegration of long-bone prostheses. Traditionally, im-
plant and patient-related demographic factors (Fig. 1) have dominated
the research focuses. Details on the biologic processes of
osseointegration is mainly derived from dental implants, experimental
animal and in vitro studies, and from autopsy retrievals (Davies, 1998;
Goriainov et al., 2014; Sychterz et al., 2002; Engh et al., 1995).
Osseointegration is deﬁned as ingrowth and/or ongrowth of new bone
to the surface of the implant (Branemark et al., 1977; Albrektsson et
al., 1981), and includes a series of biological events regulated by a vari-
ety of cells and signaling molecules. Major part of the process depends
on the actions of MSCs (Deschaseaux et al., 2009; Davies, 2003). Upon
implantation, the prosthesis gets in contact with resident and invading
MSCs, and under proper mechanical conditions, the outcome depends
on the ability of MSCs to proliferate and differentiate under inﬂuence
of growth factors and other biologically active molecules (e.g.
cytokines).
In cementless THA, initial stability of the implant is critical for suc-
cessful permanent biological osseointegration with the host bonethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig.1. Factors inﬂuencing osseointegration of cementless femoral stems. Requirements for proper biological ﬁxation are; intimate initial contact between implant and host bone, minimal
relativemotion at the implant-bone interface, appropriate implant surface characteristics and osteogenic potential at the implantation site. Initial contact andminimal relativemotion are
prerequisite for the biological processes to take place. Surface properties of the implant and quality of the host bone contribute to cellular responses and secondary ﬁxation, ultimately
determine the overall success or failure. Although implant parameters are crucial for a successful outcome, the cellular responses dictate the ﬁxation process. Implant-related (light
grey box) and patient-related (circles) factors have been extensively investigated while the role of MSCs is less understood. * indicate factors that can be controlled for. Based on
(Goriainov et al., 2014; Mellon et al., 2013; Aro et al., 2012; Moritz et al., 2011; Alm et al., 2010).
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chemical composition, surface topography, coatings), surgical
technique, and the quality of the surrounding bone bed (Goriainov
et al., 2014; Khanuja et al., 2011; Engh et al., 1987; Mellon et al., 2013)
(Fig. 1). Excessive micromotion and gaps at the interface restrain cellu-
lar processes and inhibit osteogenesis, which may delay or inhibit
osseointegration (Pilliar et al., 1986; Daugaard et al., 2011; Vandammeet al., 2011). Traditionally stem stability/ﬁxation is evaluated qualita-
tively from plain radiographs by identiﬁcation of radiographic features
including bone bridging, reactive lines, pedestal formation, calcar re-
modeling, radiolucent lines, implant position and migration exceeding
4 mm (Engh et al., 1990). Radiostereometric analysis (RSA) is a unique
method allowing for monitoring of progression of implant
osseointegration and anchorage in arthroplasty patients. The method
126 J.J. Alm et al. / Bone Reports 5 (2016) 124–135provides accurate and precise measurement of 3-dimensional implant
micromotion relative to bone (Karrholm et al., 1997; Valstar et al.,
2005). Hence, RSA measures stem ﬁxation indirectly, as
osseointegration is characterized by cessation of micromotion (Mann
et al., 2012), and by applying RSA the time point for osseointegration
can be identiﬁed. Although associated with high technical demands
and expenses, RSA is a valuable research tool offering quantitative and
early assessment of osseointegration, allowing for investigation of bio-
logical factors involved in the process in patient populations.
Although cementless THA was originally designed for middle-aged
patients with normal or close to normal bone quality, current indica-
tions have expanded to include aged patients (Troelsen et al., 2013;
Dutton and Rubash, 2008; Kelly et al., 2007; Makela et al., 2008). Post-
menopausal women constitute a majority of cementless THA patients
(Makela et al., 2008; Sadoghi et al., 2012). This patient group is prone
to osteoporosis (Glowacki et al., 2003; Makinen et al., 2007) and may
also exhibit qualitative and quantitative variations in their MSCs.
Despite the essential role of MSCs in osseointegration, there is still
little knowledge on whether intrinsic properties of MSCs, such as oste-
ogenic differentiation and the ability to lay down mineralized matrix
correlatewith the outcomeof an arthroplasty. The relationship between
in vitro properties of MSCs and biological implant ﬁxation has, to our
knowledge, never been explored in humans. Using RSA, we have inves-
tigated the impact of different bone quality parameters on the healing of
cementless THA in postmenopausal women with primary hip osteoar-
thritis (OA). We recently showed that aging, low bone mineral density
(BMD) and age-related geometric changes of the proximal femur are
risk factors for early migration and delayed osseointegration of
cementless femoral stems (Aro et al., 2012), while the quality of
intertrochanteric cancellous bone was less important for the initial
stem stability (Moritz et al., 2011). Extending our previous analysis,
we have here investigated how in vitro assayed osteogenic capacities
of patient's MSCs reﬂect in implant healing. We hypothesized that indi-
vidual variation inMSC capacitymay inﬂuence the implant healing pro-
cess, and patients with diminished osteogenic capacity of their MSCs
would show increased implantmigration and delayed osseointegration.
2. Patients and methods
2.1. Patient enrolment and surgery
The study protocol was approved by the Ethics Committee of the
Hospital District of Southwest Finland and the study was conducted in
accordance with the Code of Ethics of World Medical Association (Dec-
laration of Helsinki). All patients provided written informed consent
prior to enrollment. The original study population consisted of 61 con-
secutive generally healthy female patients b80 years of age with ad-
vanced primary hip OA scheduled for cementless THA surgery
(Makinen et al., 2007). As previously reported in detail (Makinen et
al., 2007), patients were selected for enrollment through careful screen-
ing including blood chemistry, and dual-energy x-ray absorptiometry
(DXA) measurements of BMD (at the lumbar spine, both proximal fe-
murs, and the distal non-dominant forearm) in order to exclude pa-
tients with undiagnosed metabolic bone disorders, including severe
osteoporosis (T-score b−3.5 at any anatomical site). The preoperative
DXAmeasurements were used as indicator of baseline systemic skeletal
status; patients were classiﬁed as having normal BMD (T-score N−1.0),
osteopenia (T-score between −1.0 and −2.5) or osteoporosis (T-
score b−2.5) (Makinen et al., 2007). None of the patients included in
the current analyses were on osteoporosis treatment before or after
THA (Fig. 2). All patients received vitamin D and calcium supplementa-
tion during the two-year follow-up. For subjective evaluation of func-
tional recovery, validated disease-speciﬁc scoring systems for
assessment of pain and physical function were applied at baseline and
each follow-up. Western Ontario and McMaster arthritis index
(WOMAC) was applied as a disease-speciﬁc scoring for patient-relatedoutcome, and Harris hip score (HHS) was applied as a physician assess-
ment of clinical outcome.
The patients underwent cementless THA using an RSA-marked hip
implant with proximal hydroxyapatite-coating and ceramic-ceramic
bearing surfaces (Anatomic Benoist Girard II, ABG II, Stryker), with sub-
sequent two-year RSA follow-up of implant healing as described previ-
ously (Aro et al., 2012). For analyses of MSCs, the patients underwent
bonemarrow aspiration from the posterior iliac crest under spinal anes-
thesia prior to surgery. Of the 53 eligible patients (Makinen et al., 2007),
MSCs were isolated, cultured and analyzed for osteogenic differentia-
tion capacity frombonemarrow samples of 30 patients (Supplementary
Table 1).
2.2. Radiostereometric analysis of femoral stem migration and
osseointegration
Three-dimensional migration of the anatomically shaped RSA-
marked femoral stem (Fig. 3A) was evaluated using uniplanar RSA im-
aging technique at baseline (within 7 days after surgery) and at 3, 6,
12 and 24 months after surgery (Fig. 3B-C). RSA examination was
done using UmRSA 6.0.3.7 software (RSA BioMedical Innovations AB,
Umeå, Sweden). Migration of the stemwas analyzed as translation (lin-
earmovements) and rotation (angularmovements) along three axes (y,
x, z) (Fig. 3D). Translational migration along the y-axis (i.e. stem subsi-
dence) and rotation around the y-axis were used as main parameters.
As an expression of three-dimensional translational and rotational
movements, the translation vector and the rotation vector were calcu-
lated, respectively (Kaptein et al., 2007). Analyses were performed ac-
cording to the RSA guidelines (Karrholm et al., 1997; Valstar et al.,
2005).
The traditional RSA measurements describe change in implant posi-
tion at each follow-up time point compared to baseline. In addition, we
calculated the cumulative migration detected between follow-up time
points (3 to 6 months + 6 to 12 months + 12 to 24 months) as a mea-
sure of total distance of migration. Since most cementless stem designs
display some degree of migration, mostly subsidence, during the set-
tling period of the ﬁrst 3 postoperative months, we chose the cumula-
tive migration from 3 to 24 months as a measure to discriminate
between normal expected migration and additional migration that can
be more clinically relevant.
RSA data was further used to assess stem osseointegration (i.e. im-
plant stability as sign of complete healing) at the individual patient
level (Aro et al., 2012). At each time point, stems were classiﬁed as
ﬁxed (osseointegrated) or migrating by comparing to stem position at
the preceding time point. The stem was deﬁned as migrating if change
in stem position exceeded the precision values of the RSA measure-
ments (0.42 mm for y-translation, 0.40 mm for translation vector, 1.81
degrees for y-rotation, and 1.32 degrees for the rotation vector), deﬁned
by double examinations (Moritz et al., 2011).
The two-year postoperative RSA follow-up of femoral stemmigration
was successfully completed from 19 patients (age 65 ± 8, 50–78 years),
including four with normal systemic BMD, 12 with osteopenia and three
with osteoporosis. All patients had femur morphology corresponding to
Dorr type A (N= 12) or type B (N= 7). Eleven patients were excluded
from the RSA follow-up analysis due to; initiation of antiresorptive drug
therapy for severe osteoporosis (N= 9), surgical complication (N= 1),
or absence of RSA markers (N= 1) (Fig. 2).
2.3. Isolation and culture of bone marrow MSCs
MSCswere isolated from the BM aspirates (3–5 mL) and cultured as
described previously (Alm et al., 2010; Alm et al., 2012). Brieﬂy, density
gradient isolated mononuclear cells were seeded at 80,000 cells/cm2
and cultured in phenol red free alpha-MEM (Gibco Invitrogen) supple-
mented with 10% fetal calf serum (Gibco Invitrogen cat. #16000) and
penicillin-streptomycin (Gibco Invitrogen) as the basal medium. Non-
Fig. 2. Study design.
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were re-plated at 1000 cells/cm2 and expanded through several pas-
sages. IsolatedMSCswere characterized (Alm et al., 2010) by successful
expansion and differentiation into osteoblasts and adipocytes. The MSC
phenotype (CD105+, CD73+, CD90+, CD45− and CD14−) and
chondrogenic differentiation capacity was conﬁrmed in a subgroup by
immunocytochemistry and micromass cultures, respectively, according
to the ISCTminimal criteria (Dominici et al., 2006). Proliferative capacity
was evaluated by calculating the number of cell population doublings
(PDs) at each passage using the formula log N/log 2 (N is the number
of cells at harvest divided by the number of cells plated).
2.4. Osteogenic differentiation
For assessment of osteogenic differentiation capacity, passage 1–3
MSCswere seeded at 2500 cells/cm2 in four replicate wells and culturedin basal medium supplemented with 10 mM sodium β-glycerophos-
phate (Merck) and 0.05 mM ascorbic acid-2-phosphate (Sigma-Al-
drich). During the ﬁrst 7 days of induction, 100 nM dexamethasone
(Sigma-Aldrich) was used as an additional supplement (Alm et al.,
2012). Parallel cultures in basal medium served as control. Osteogenic
differentiationwas demonstrated by analyzing for alkaline phosphatase
(ALP). ALP activity wasmeasured spectrophotometrically after 2 weeks
in osteogenic culture medium. ALP activity was converted to units/μg
protein. After 4–5 weeks in osteogenic medium, cultures were stained
for ALP (ALP kit, Sigma Diagnostics, St. Louis, MO, USA). As a measure
of complete differentiation into functional osteoblasts, extracellularma-
trix mineralization was analyzed with von Kossa staining and by spec-
trophotometric measurement of deposited calcium using a
commercial kit (Roche Diagnostics). ALP and von Kossa stainings were
quantiﬁed histomorphometrically using an automated image analysis
as described previously (Alm et al., 2012). Brieﬂy, the stained plates
Fig. 3. Radiostereometric analysis of the cementless femoral stem. (A) The ABG-II titaniumalloy stemwith proximal hydroxyapatite coating, polished distal part and ceramic head. The
six tantalum RSA markers are indicated with arrows. (B) Schematic drawing of radiographic examination of the operated hip with simultaneous exposure of two X-ray units. UmRSA
calibration cage with X-ray plates under the examination table. (C) Postoperative radiograph of a prosthesis with six visible RSA bone markers in the surrounding proximal femur
indicated with arrows. (D) Schematic drawing of the prosthesis with RSA tantalum markers on the implant and in the surrounding bone, along with the coordinate system for RSA
analysis of three-dimensional stem migration in relation to the femur (D).
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ScanJet 5370C) and a custom-designed holder for accurate and repro-
ducible positioning of the plates during scanning at 600 dpi. Transpar-
ency exposure adjustments were kept constant to generate images of
equal intensity, and images were saved as 24-bit color images in TIF for-
mat. Images were analyzed using the automated image analysis soft-
ware and the stained area (cm2) was converted to percentage of the
total area and presented asmeanpercentage stained area from four rep-
licate wells.
2.5. Assessment of osteogenic capacity of MSCs
MSCs from all donors (N=30, Supplementary Table 1) demonstrated
osteogenic differentiation, although at varying degree, but the level ofmin-
eralization was generally low and complete mineralization was detectable
only for MSCs from part of the patients (Supplementary Table 2, Supple-
mentary Fig. 1). From 13 patients out of 30, no matrix mineralizationcould be detected despite repeated osteogenic culturing at twoor three dif-
ferent passages (p1–3). These MSCs were hence classiﬁed as negative for
mineralization. Therefore, for thepurposes of analyzing the relationship be-
tween in vitro osteogenic differentiation capacity of MSCs and hip implant
migration (N= 19, Fig. 2), patients were classiﬁed as having MSCs with
high or low osteogenic (OB) capacity based on the combined ALP andmin-
eralization outcome. First, the patients were ranked for the osteogenic dif-
ferentiation capacity, i.e. ALP stained area, by arranging the data in
ascending order and dividing into 1) low, 2) middle and 3) high index
groups of equal size. Second, the patients were ranked for the mineraliza-
tion capacity of their MSCs, i.e., von Kossa stained area, using the same
method. Thereafter, the OB-capacity groups were obtained by calculating
the sum of the ALP and the mineralization indexes for each patient. The
low OB-capacity groupwas deﬁned as patients with a combined index be-
tween 2 and 4 (N= 12), and the high OB-capacity group was deﬁned as
patients with a combined index of 5 and 6 (N=7). This strategy ensured
the high OB-capacity group did not include any patient with low ranking
Table 1
Demographic and clinical characteristics of postmenopausal female THA patients (N= 19).
Demographics (Mean ± SD, range) Low OB-capacity MSCs (N= 12) High OB-capacity MSCs (N= 7) p-valuea
Age 66 ± 8 (50–78) 63 ± 7 (55–73) 0.520
BMI 31 ± 5 (23–39) 30 ± 6 (24–38) 0.708
S-25(OH)D (nmol/L) (normal, 50–140) 52 ± 19 (30–93) 65 ± 33 (19–106) 0.294
S-PTH (ng/L) (normal, 10–55) 40 ± 12 (20–58) 37 ± 7 (24–45) 0.682
Lowest T-score −1.7 ± 1.0 (−3.5 to−0.2) −1.4 ± 0.9 (−2.4 to 0.2) 0.531
Bone mineral density (g/cm2)
Contralateral hip, femoral neck 0.78 ± 15 (0.62–1.11) 0.79 ± 0.09 (0.71–0.95) 0.919
Non-dominant forearm, total distal radius 0.54 ± 0.05 (0.43–0.62) 0.54 ± 0.06 (0.49–0.62) 0.849
Lumbar spine, total 1.10 ± 0.17 (0.71–1.44) 1.03 ± 0.14 (0.87–1.18) 0.788
Serum markers of bone turnover (mean ± SD, range)
Bone ALP (U/L) (normal b69) 37 ± 19 (13–81) 36 ± 14 (21–57) 0.911
Intact PINP (μg/L) (normal, 19–84) 51 ± 22 (26–97) 59 ± 21 (45–98) 0.501
OCN (μg/L) (normal, 8–56) 23 ± 12 (6–43) 20 ± 7 (14–30) 0.590
CTX (nM/L) (normal, 0.112–0.738) 0.54 ± 0.32 (0.20–1.29) 0.46 ± 0.12 (0.35–0.65) 0.553
NTX (nM/L) (normal, 6.2–19) 11 ± 4 (4–18) 10 ± 4 (7–16) 0.920
TRACP-5b (U/L) (normal, 1.4–4.2) 3.7 ± 1.4 (1.2–5.6) 4.1 ± 1.3 (2.8–6.5) 0.533
Frequencies, N (%) p-valueb
Systemic BMD 0.308
Normal BMD 3 (25%) 1 (14%)
Osteopenia 6 (50%) 6 (86%)
Osteoporosis 3 (25%) 0 (0%)
Dorr classiﬁcation of proximal femur geometry 0.960
Type A 7 (58%) 4 (57%)
Type B 5 (42%) 3 (43%)
25(OH)D insufﬁciency (b50 nmol/L) 6 (50%) 3 (43%) 0.502
Previous fracture 4 (33%) 1 (14%) 0.394
Estrogen replacement 4 (33%) 1 (14%) 0.457
Smoking 1 (8%) 1 (14%) 0.467
Alcohol consumption, N 3 drinks/week 2 (17%) 2 (28%) 0.828
Disease-speciﬁc scores for evaluation of hip OA (Mean ± SD, range) p-valuea
Harris hip score Preoperative 53 ± 18 (17–84) 52 ± 15 (26–68) 0.902
24 months postoperatively 79 ± 21 (42–100) 89 ± 10 (74–100) 0.289
WOMAC score Preoperative 51 ± 13 (32–77) 62 ± 18 (39–77) 0.213
24 months postoperatively 21 ± 19 (0–59) 16 ± 10 (6–26) 0.613
a p= two-tailed p-value from Student's T-test.
b p-value from chi-square test; OB= osteogenic differentiation; OB-capacity groups based on combined quartiles from ALP and mineralization; ALP = alkaline phosphatase; PINP =
procollagen type I propeptide; OCN = Osteocalcin; CTX = C-terminal crosslinking telopeptide of type I collagen; NTX = N-terminal crosslinking telopeptide of type I collagen;
TRACP-5b = Tartrate-resistant acid phosphatase type 5b.
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for details on the classiﬁcation process.
2.6. Statistical analysis
The data is shown asmean± SD (range). A signiﬁcance level of 0.05
was applied. Comparisons between the low and high OB-capacity
groups were done using Student's T-test after conﬁrming that data ful-
ﬁlled the criteria (normal distribution and equal variances). Possible in-
ﬂuence of confounding demographic and clinical factors on the
outcome was ruled out by separate linear correlation analyses with
the study main parameters (MSC data and RSA data, respectively). In
analysis of mean change in femoral stem position over time in the two
subgroups, it was ensured that the RSA data did not include outlier
values. Prior to all correlation analyses, datawas checked for normal dis-
tribution and outliers. Kaplan-Meier time-to-event estimates were ap-
plied to analyze differences in osseointegration time point. Statistical
analyses were performed using IBM SPSS Statistics 22 software.
3. Results
3.1. RSA measured change in femoral stem position
The two-year postoperative RSA follow-up of femoral stem migration
was successfully completed from 19 patients (Tables 1 and 2) who were
classiﬁed as having MSCs with high (N= 7) or low (N= 12) osteogenic(OB) capacity based on the combined ALP and mineralization outcome. In
patients with MSCs of low OB-capacity, the mean change in stem position
along the y-axis (stem subsidence) at 3 and 24 months was more than
twice that in patients with MSCs of high OB-capacity, although this differ-
ence did not reach statistical signiﬁcance (Table 3, Fig. 4A). A similar
trend was seen for the three-dimensional translation (translation vector).
However, in the low OB-capacity group, stem subsidence signiﬁcantly
exceeded the detection limit (0.42 mm) for stem migration by 3 months
(p = 0.020), which was not seen in the high OB-capacity group (p =
0.351). Also for the translation vector, migration signiﬁcantly exceeded
the speciﬁc detection limit (0.40 mm) in the low (p= 0.015), but not in
the high (p= 0.451) OB-capacity group. Change in stem position around
the y-axis (stem rotation), as well as the three-dimensional rotation (rota-
tion vector), were of similar magnitude in the two OB-capacity groups
(Table 3, Fig. 4B).
3.2. Cumulative femoral stem migration after the 3 months settling period
In the whole group of 19 patients, the calculated cumulative migra-
tion from 3 to 24months ranged between 0.1 and 2.2 mm (mean 0.6 ±
0.5) along the y-axis (stem subsidence) and between 1.1 and 6.6 de-
grees (mean 3.0±1.5) rotation around the y-axis. Themagnitude of cu-
mulative stem subsidence from 3 to 24months was signiﬁcantly higher
in patients with MSCs of low in vitro OB-capacity (p= 0.028)(Fig. 5A),
as was the magnitude of cumulative three-dimensional translation
(translation vector, p= 0.043)(Fig. 5B). The cumulative rotation along
Table 2
Iliac crest BM-MSC characteristics of postmenopausal THA patients (N= 19).
Mean ± SD Range
BM aspirate cellularity
MNCs (106)/mL bone marrow 3.6 ± 6.4 0.2–30
CFU/BM MNCs (%) 0.003 ± 0.002 0.001–0.008
Growth capacity (maximum value passage 1–3)
Max population doublings 3.9 ± 1.4 1.0–6.9
Max population doubling rate (PDs/day) 0.12 ± 0.07 0.02–0.27
Osteogenic differentiation capacity
ALP activity (U/g protein) 12 ± 5 7–23
ALP stained area (%) 34 ± 27 1–90
von Kossa stained area (%) 12 ± 15a
32 ± 13b
0–52
5–52
Ca (mmol/L) 0.16 ± 0.14 0.07–0.62
a All donors, including zero values.
b Only values N0 included.
Fig. 4. RSA-measured change in femoral stem position up to 24-months after surgery.
Three-dimensional (A) translation (translation vector) and (B) rotation (rotation vector)
of the cementless femoral stem in female patients with MSCs of low or high osteogenic
capacity. In patients with MSCs of low OB-capacity, translational change in stem position
signiﬁcantly (p = 0.015) exceeded the detection limit (dotted line), indicating
migration. Dotted lines indicate the parameter-speciﬁc detection limits. Data presented
as mean with SD.
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varied widely between subjects, with corresponding magnitude in the
twoOB-capacity groups (Fig. 5C-D). Importantly, differences in cumula-
tive translational migration between patients with MSCs of high or low
OB-capacity were not due to underlying demographic or clinical con-
founders, since there were no differences in these parameters between
the two groups (Table 1). In addition, the linear correlation analyses be-
tween the dependent variables and possible confounders showed no
interactions.
3.3. In vitro osteogenic capacity of MSCs as predictor of time point for
osseointegration
The time point for translational and rotational stemosseointegration
was assessed for each individual patient based on translation and rota-
tion vectors, respectively. Difference in osseointegration time point be-
tween patientswith high and low in vitroOB-capacity of theirMSCswas
investigated with Kaplan-Meier time-to-event estimates, although the
results should be interpretedwith caution due to the low number of pa-
tients. For translational osseointegration, the estimate was signiﬁcantly
different between the two groups (p = 0.030). Patients with MSCs of
high OB-capacity had a 43% probability of translational osseointegration
within 3 months and a 100% probability of osseointegration within
6 months. In contrast, none of the patients with MSCs of low OB-Table 3
RSA-measured femoral stem migration (change in stem position) in patients with high and low OB-capacity of their bone marrowMSCs.
Low OB-capacity (N= 12) High OB-capacity (N= 7) Mean difference 95% conﬁdence interval p
Stem subsidence (y) (mm)
(detection limit 0.42 mm)
3 months 1.4 ± 1.2* 0.6 ± 0.5 0.8 −0.1 to 1.6 0.070
24 months 1.5 ± 1.2* 0.6 ± 0.7 0.9 −0.1 to 1.9 0.083
Translation vector (x,y,z) (mm)
(detection limit 0.40 mm)
3 months 1.6 ± 1.3** 0.7 ± 0.6 0.9 −0.05 to 2.0 0.060
24 months 1.8 ± 1.2** 0.8 ± 0.6 0.9 −0.04 to 1.9 0.058
Stem rotation (y)(degrees)
(detection limit 1.81 degrees)
3 months 1.5 ± 0.8 1.1 ± 1.2 0.4 −0.5 to 1.4 0.366
24 months 2.1 ± 1.7 0.9 ± 0.6 1.1 −0.2 to 2.4 0.058
Rotation vector (x, y, z) (degrees)
(detection limit 1.32 degrees)
3 months 1.8 ± 0.8 1.2 ± 1.1 0.6 −0.3 to 1.5 0.193
24 months 2.6 ± 2.2 1.2 ± 0.5 1.4 −0.2 to 3.0 0.074
Change in stem position along the y-axis (proximal/distal) represents stem subsidence; change in stem position around the y-axis (retroversion/anteversion) represents stem rotation;
vectors represent three-dimensional migration along (translation) or around (rotation) three axes (x, y, z); stem subsidence and rotation are presented as mean of absolute (unsigned)
values; asterisks indicate migration signiﬁcantly exceeding the detection limit, i.e. the stability limit, compared to baseline (*p b 0.05, **p b 0.01); OB= osteogenic differentiation; OB-ca-
pacity groups based on combined quartiles from ALP andmineralization; p= two-tailed p-value from Student's T-test for comparison between the low and the high OB-capacity groups.
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but had 73% probability of osseointegration within 6 months, and 91%
probability of osseointegration within 12 months. There was no signiﬁ-
cant difference in estimates of rotational osseointegration between the
groups. The estimated probability for osseointegration within 3months
was 57% in the high OB-capacity group and 25% in the low OB-capacity
group (Supplementary Table 3).
The RSA-measured stem migration had no impact on the subjective
or functional recovery from the hip replacement. There were no signif-
icant preoperative or postoperative differences in either WOMAC or
HHS scores between the two groups (Table 1). Both groups showed a
signiﬁcant improvement of the outcome measures postoperatively
(p b 0.001 for both). At 24 months, there were no signs of radiographic
implant loosening or any other reason for revision surgery.
In one patient, the femoral stem had not yet stabilized by 24months.
In this patient, the total distance of translational migration from base-
line to 24 months was 2.2 mm, and rotational migration was 4.4 de-
grees. There were no signs of stem loosening on plain radiographs,
and the patient reported only minimal pain. This patient was
osteopenic, had Dorr type A femur, showed signs of high bone turnover
in the preoperative screening of serummarkers, and was insufﬁcient in
25(OH)D (43 nmol/L). The bone marrow MSCs of this patient showed
slow growth rate, with only 1.1 PDs reached during passage 1. WhenFig. 5. Cumulative stem migration from 3 to 24 months. In patients with MSCs of low osteoge
subsidence) and (B) in three-dimensional translation (translation vector) was signiﬁcantly hi
rotational migration around the y-axis (stem rotation), and (D) three-dimensional rotation (r
95% conﬁdence interval. p= two-tailed p-value from Student's T-test. Dotted lines indicate paculturing in osteogenicmedia cells were negative for both ALP andmin-
eralization, despite repeated experiments (passage 2 and 3).
3.4. In vitro osteogenic properties ofMSCs correlate with clinical bone qual-
ity parameters
To further investigate the relevance of in vitro testing of osteogenic
capacity of bone marrowMSCs in relation to bone health of the donors,
analyses were performed including all the study patients who had suc-
cessful iliac crest bone marrow aspirate before THA surgery (N = 30)
(Fig. 2, Supplementary Table 1). In linear correlation analyses, ALP
stained areaswasused as ameasure of in vitro osteogenic differentiation
capacity (Fig. 6). MSCs from subjects with low preoperative T-score
showed decreased osteogenic differentiation (r = 0.42, p = 0.019,
N = 30)(Fig. 6A). There was an inverse relationship between in vitro
ALP expression and serum levels of vitamin D (25(OH)D)(r =−0.42,
p= 0.021, N= 30) (Fig. 6B). Further, ALP levels in MSC cultures corre-
lated with serum levels of bone formation marker ALP (r = 0.38, p =
0.045, N = 28) (Fig. 6C) and bone resorption marker TRACP-5b (r =
0.50, p= 0.006, N= 28) (Fig. 6D).
Patients whose MSCs failed to produce mineralized matrix in vitro
(N = 13) had signiﬁcantly lower systemic BMD (lowest T-score −
3.1 ± 1.6) compared to patients with MSCs capable of in vitronic capacity (N= 12) the magnitude of cumulative migration (A) along the y-axis (stem
gher compared to the high OB-capacity group (N= 7). The magnitude of cumulative (C)
otation vector) was similar in the two OB-capacity groups. Data presented as mean with
rameter-speciﬁc detection limits, i.e., limits of detectable migration.
Fig. 6. Correlations between clinical parameters of bone quality and in vitro osteogenic differentiation capacity of the patients' bonemarrowMSCs. The osteogenic differentiation capacity
of theMSCs, represented by expression of alkaline phosphatase (ALP), correlated signiﬁcantlywith (A) the DXA-measured lowest T-score (lumbar spine, proximal femurs, non-dominant
forearm) of the patients (N=30). Dotted lines indicate T-score limit for osteopenia (upper line) and osteoporosis (lower line), respectively. (B) Therewas an inverse correlation between
MSC-expressed ALP and serum levels of 25(OH)D (N= 30). Dotted line indicate limit for vitamin D insufﬁciency. Osteogenic differentiation capacity of MSCs also correlated with serum
levels of (C) bone formationmarker bone ALP (N=28), and (D) serum levels of resorptionmarker TRACP-5b (N=28) (D) (dotted lines indicate normal ranges). r=Pearson correlation
coefﬁcient; p= two-tailed p-value.
132 J.J. Alm et al. / Bone Reports 5 (2016) 124–135mineralization (N=17)(lowest T-score− 1.9 ± 1.1, p=0.044). There
were no differences in serum levels of bone turnovermarkers, 25(OH)D
or PTH levels between themineralization groups. There were no associ-
ations between in vitro osteogenic differentiation (ALP or mineraliza-
tion) with age or BMI in the present patient population.
4. Discussion
This study explored how in vitro osteogenic capacity of bonemarrow
MSCs from postmenopausal women undergoing cementless THA re-
ﬂects implant osseointegration, representing the patient's in vivo bone
healing capacity. RSA monitoring of three-dimensional migration of
the cementless femoral stems conﬁrmed our hypothesis, demonstrating
that patients withMSCs of low in vitro osteogenic capacity displayed in-
creased stem subsidence after the settling period of 3 months, and
thereby delayed osseointegration.
Although MSCs have an essential role in cementless hip implant
healing, this is difﬁcult to prove in clinical settings due to numerous
overshadowing implant and patient related factors traditionally identi-
ﬁed to dictate successful osseointegration. A remaining question is
whether osseointegration in patients undergoing cementless THA ismir-
rored by the in vitro ability of their MSCs to differentiate into bone cells
and mineralize under osteogenic culture conditions. Development of
thehighly accurate RSA imaging technology has revolutionized our capa-
bilities formonitoring the process of implant healing (Valstar et al., 2012;
de Vries et al., 2014). By allowing measurements of micromotions not
detectable with other imaging methods, stability/ﬁxation of the stem
can be indirectly measured, and RSA makes it possible to investigatethe impact of unexplored biological elements, including MSCs, on bone
healing in cementless THA patients, reaching beyond the conventional
implant related and biomechanical factors. In order to demonstrate the
role of MSCs in the progress of cementless implant healing in clinical
studies, the key is to minimize the many possible confounding factors
by applying strict exclusion criteria, yet to select patients with increased
potential of exhibiting a certain degree of implantmicromigration before
eventual osseointegration. For example, in younger (b65-years old)
male and female patient populations with good skeletal health RSA-mi-
gration is minimal or not detectable. Postmenopausal agingwomen rep-
resent this type of an ideal study population not only for the scientiﬁc
purpose but for the clinical relevance based on the fact that: (1) post-
menopausal women represent the largest group of patients undergoing
THA (Makela et al., 2008; Sadoghi et al., 2012), (2) they are prone to im-
paired skeletal quality with increased risk of complications including de-
layed osseointegration (Vandamme et al., 2011; Marco et al., 2005) and
periprosthetic fractures (Sidler-Maier and Waddell, 2015), and (3) they
display an age-related decrease of MSC capacity (Kassem and Marie,
2011; Baker et al., 2015). In the current study, the selected patients
were postmenopausal women who suffered from primary hip OA but
were otherwise healthy and without bone-affecting medication. They
underwent standardized surgical procedure performed by a single expe-
rienced orthopedic surgeon, receiving the ABGII anatomically-shaped
femoral stem size-ﬁtted to obtain optimal press-ﬁtting, further limiting
possible confounding factors.
We believe that our results on increased femoral stem subsidence in
patients with decreased in vitroOB-capacity of theirMSCs truly demon-
strates a relationship between MSC properties and hip implant healing
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well balanced in terms of important demographic parameters, including
age, systemic and local BMD, rate of bone turnover, S-25(OH)D status,
and life style. The impact of demographic confounders known to affect
not only implant osseointegration but also MSC number, quality and
functions was further ruled out by correlation analyses. Although anal-
yses of MSCs from the whole group of recruited patients (N = 30)
showed correlations between OB-capacity and clinical bone quality pa-
rameters, such correlations were not present for the 19 patients consti-
tuting the main study population. As we previously demonstrated (Aro
et al., 2012), the geometry of the proximal femur is a signiﬁcant factor
affecting stem migration. Importantly, proximal femur geometry was
ruled out as a confounding factor in the current analysis, and the
study constituted only patients with Dorr type A and B shaped femurs
equally distributed between the two OB-capacity groups.
It is important to emphasize that the magnitude of cumulative stem
subsidence from 3 to 24monthswas small both in the low and high OB-
capacity patients (0.7 mm and 0.3 mm, respectively) despite the statis-
tical difference between the two groups. This magnitude of stem subsi-
dence was not detectable on radiographs or associated with
radiographic signs of loosening. The functional recovery of the patients
was also uneventful and there was no need for revisions. These ﬁndings
are in well agreement with recent registry studies showing excellent
10-year survival (99% for the ABG stem) for cementless femoral stems
of current designs (Hailer et al., 2015). Thus, the decreased OB-capacity
of MSCs seen in our patient group is associated with subclinical stem
migration and delayed stabilization, resembling the clinical event of os-
teoporotic fracture healing. In experimental models of osteoporosis
(Egermann et al., 2008) the rate of bone fracture healing is decreased,
while in patients, fractures heal in a fairly predictable manner despite
osteoporotic conditions. However, this does not diminish the scientiﬁc
value of the current results. On the contrary, our study suggests that in
vitro analysis of the “osteogenic ﬁtness” of the MSC reservoir may
serve as a unique clinical model to verify and evaluate the role of
MSCs in the biological process of implant healing, particularly in pa-
tientswith age-related dysfunction ofMSCs and decreased bonehealing
capacity. In vitro and experimental animal studies have demonstrated
the signiﬁcant inﬂuences of implant topography and surface properties
on MSCs attachment and differentiation and thereby implant ﬁxation
(Goriainov et al., 2014). Microrough surfaces stimulates osteogenic dif-
ferentiation of MSCs through activation of the non-canonical Wnt sig-
naling pathway (Olivares-Navarrete et al., 2011), while
hydroxyapatite coating is a strong activator of the canonicalWnt signal-
ing pathway (Thorfve et al., 2014). Our clinical study further supports
efforts focusing on improving implant ﬁxation through surface modiﬁ-
cations affectingMSCs (Goriainov et al., 2014),which could compensate
for decreased OB-capacity of the MSCs.
It can be argued that the use of cemented ﬁxation could provide an
attractive alternative in patients at risk of decreasedMSC capacity. How-
ever, MSCs may also have a role in the long-term success of cemented
prostheses. Cement ﬁxation relies onmechanical interlocking in cancel-
lous bone regions, but failed osteogenic function of MSCs may impair
bone remodeling, leading to structural weakness of periprosthetic can-
cellous bone and subsequentmechanical loosening of a cemented pros-
thesis. Clinical reports indicate that osteoporosis is a risk factor for late
mechanical loosening of cemented hip prostheses (Broden et al.,
2015). In our opinion, the osteogenic capacity of MSCs may be impor-
tant also for the long-term survival of cemented hip prostheses, al-
though this is still an unexplored ﬁeld of research.
Expression of ALP is a measure of early osteoblastic differentiation,
while mineralization is a late marker of complete differentiation into
matrix producing osteoblasts. Since both properties are essential in
terms of osseointegration, we divided the patients into low and high
OB-capacity groups based on the combined ALP andmineralization out-
comes for the purposes of analyzing the relationship between in vitro
osteogenic capacity of MSCs and hip implant migration. The rankingstrategy for indexing the differentiation and mineralization properties
separately, followed by calculation of a combined index, represents a
fairly objective way of dividing the groups based on in vitro properties
of the patients'MSCs. The approach to include only patientswith a com-
bined index of 5 or 6 to the high capacity group ensured that patients
with the lowest ranking index in either of the parameters (differentia-
tion or mineralization) were designated as low OB-capacity regardless
of ranking in the other parameter. Although this produced unequal
group sizes, it should impartially reﬂect a general level of MSCs' osteo-
genic capacity within this study population.
A number of signaling molecules are involved in MSC survival, pro-
liferation, recruitment, activation and differentiation. Individual varia-
tion in endogenous levels of such factors could contribute to
differences in both in vitroproperties ofMSC aswell as in vivo properties
of MSCs affecting the healing responses upon THA surgery, although
clinical evidences are limited. Increased serum levels of BMP-2 have
been found in patients with knee OA compared to healthy controls
(Liu et al., 2015). Such variations in BMP-2 levels cannot be ruled out
as an underlying contributing factor to the observed differences in OB-
capacity and osseointegration in the current study. However, patients
with normal and delayed fracture healing have similar levels of circulat-
ing BMPs (van Baardewijk et al., 2013). Circulating level of TGF-β1 is an-
other crucial factor affecting MSC differentiation, demonstrated to
increase after fracture (Sarahrudi et al., 2011) and displaying different
time-dependent levels in normal compared to delayed fracture healing
(Zimmermann et al., 2005). Currently, there are no corresponding data
available regarding THA.
The aim of this study was not to investigate the correlation between
MSC properties and demographic parameters; rather this was per-
formed as secondary, post hoc, analyses including MSCs from the
whole study population of 30 THA females. The correlations found
were not strong, but yet statistically signiﬁcant. Our results are in line
with established observations of associations between in vitro osteogen-
ic differentiation of MSCs and clinical bone quality parameters of the
subjects. MSCs from patients with higher systemic BMD and higher
bone turnover showed increased osteogenic differentiation capacity.
The correlation of ALP expression with preoperative T-scores and in-
verse correlation with serum vitamin D corresponds to results by
Zhou et al. (Zhou et al., 2012). Their detailed analyses revealed an in-
creased in vitro response of MSCs from vitamin D deﬁcient patients to
osteogenic culture conditions, explaining the inverse relationship. In
contrast to their study, we did not ﬁnd a correlation between serum
PTH levels and osteogenic differentiation of MSCs, which could be ex-
plained by the higher PTH levels in our study. The weak correlations
in the current study (explaining 14–25% of the MSC ALP expression)
and in the study by Zhou et al. (Zhou et al., 2012) (explaining 13–
24%) probably reﬂect the discrepancy between artiﬁcial and simpliﬁed
in vitro conditions and the true complex in vivo situation. As a general
observation, cell yield, expansion capacity and osteogenic differentia-
tion properties of MSCs from the current group of postmenopausal
THA females varied widely and were approximately 50% compared to
MSCs from younger premenopausal females (mean age 40 ± 16,
range 19–60) from our previous studies (Alm et al., 2010).
This study carries both strengths and limitations. The homogenous
and carefully screened female population brought strength to our
study, alongwith application of the sophisticated RSAmethod for mon-
itoring of implant micromigration, in combination with analysis of indi-
vidual patients' MSCs. However, the RSA method carries certain
limitations, mainly related to the technical demands and high costs.
Every aspect of the method has to be meticulously followed in order
to obtain valid outcomes, and it is time-consuming. Our group has
paid great attention to standardize the applied RSA technology using a
phantom model (Makinen et al., 2004; Madanat et al., 2014), and the
CE-certiﬁed implant was custom-modiﬁed by a leading international
manufacturer in order to assure accuracy and precision. RSA imaging
and analysis were performed by two trained technicians and an
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own pitfalls. Analyzing mean values, according to the RSA guidelines
(Valstar et al., 2005), is useful when evaluating performance of new im-
plant designs or investigating the impact of medical intervention, but
provide limited information at the individual patient level. Since what
is actually measured is the change in stem position compared to base-
line, the true distance of migration over time gets hidden when mean
values are presented. We therefore extended the traditional RSA data
analyses by assessing stemmigration over time separately for each indi-
vidual patient for identiﬁcation of time point of osseointegration/stabi-
lization, and by evaluation of cumulative distance of migration taking
place after the initial 3 months settling period. For iliac crest bone mar-
row aspirations, standardized techniques were adopted (Muschler et
al., 1997) and we have optimized the MSC culturing protocols (Alm et
al., 2012). Through the approach to divide patients into low and high
OB-capacity groups the limited statistical power due to large variability
in the MSC data was evaded. Large inter-individual variability is a well-
documented reality associated with human MSCs. Increasing the num-
ber of patients could have increased the statistical power of our study
and allowed for other statistical approaches, but to fully overcome the
large variations the numberwould need to be unrealistically high, espe-
cially in this type of prospective study. This study did not include gene
expression analysis of the MSCs. Such analysis could possibly have ex-
posed differences in expression patterns of key osteogenic genes
(RUNX2, OSX, ALP, COL1, OCN) or even frequencies of committed
MSCs from different patients, contributing to understanding the under-
lying mechanisms to the observed low and high in vitro osteogenic ca-
pacities. However, gene expression levels do not always correspond to
the actual protein levels, and do not reﬂect the osteogenic functionality
of the cells. This study do not delineate the possible impact of gender,
type of cementless stem or cement ﬁxation on the relation between
MSC capacity and stem osseointegration. The impact of the speciﬁc
stem design (ABGII) used in this study should not be neglected. With
straight non-anatomical designs relying on 3-pont ﬁxation, or tapered
stems the migration patterns would most likely be different, and the
correlation to MSC capacity could also show different trends. Since the
physical activity level of the patients was not analyzed in the current
study, possible underlying effects of this factor on both the RSA data
and MSCs capacity levels cannot be evaluated. The rate of drop-outs
was low during the follow-up, but the power of our study was limited
due to low number of patients with concomitant successful MSC analy-
sis and RSA follow-up. This was not surprising taking into account that
both methods are demanding and the current study represents to our
knowledge the ﬁrst of its kind. With its high accuracy and precision,
RSA allows minimizing the sample size. The size of the recruited cohort
(N= 30) and the number of patients completing the two-year follow-
up (N = 19) were within the recommended minimum group size of
15–25 patients in RSA studies (Valstar et al., 2005), but the MSC sub-
groups were undersized. Further research is warranted for more de-
tailed analyses of underlying and contributing mechanisms.
5. Conclusions
In this prospective clinical study we analyzed the preoperative in
vitro osteogenic capacity of bone marrow MSCs from postmenopausal
women undergoing cementless total hip replacement, in combination
with a 2-year postoperative radiostereometric monitoring of their fem-
oral stem migration. We assumed that the rate of hip stem
osseointegration partly reﬂects the patients' MSC capacity, along with
other known factors affecting osseointegration (Fig. 1). The results dem-
onstrated increased cumulativemigration and delayed osseointegration
of femoral stems in patients with low MSCs osteogenic capacity. Our
study presents a novel approach for studying the biological progress of
hip implant osseointegration and to verify the impact of decreased
MSC function. Since the RSA method allows detection of subclinical
micromotions of cementless hip implants, subjects with impairedimplant healing can be identiﬁed. Individualized aspects are emerging
in orthopaedic medicine, where MSCs present a key tool in tailoring fu-
ture improved implant osseointegration (Lewallen et al., 2014). Results
from our previous studies suggest that (female) patients scheduled for
cementless THA should be more carefully screened for systemic BMD
status (DXA), secondary causes of osteoporosis (laboratory tests), and
geometric femoral changes of the affected hip in order to identify pa-
tients at risk of delayed implant healing (Makinen et al., 2007; Aro et
al., 2012). Extending these clinical assays, the current study suggests
that analysis of autologous MSC properties is an aspect to consider, es-
pecially in patients with decreased bone quality, and/or in patients
scheduled for more challenging bone reconstructive surgeries, where
“boosting” of bone formation can be of relevance. Considering current
efforts focusing on boosting, mobilization and homing of endogenous
MSCs for enhancement of bone repair (Herrmann et al., 2015), preoper-
ative in vitro evaluations of the patients' MSCs for guidance of appropri-
ate approach for the individual patient could be useful. Both RSA
imaging technique and MSC analysis are internationally established
and ethically approved. However, these methods are technically chal-
lenging, time-consuming, expensive and labor requiring, especially in
prospective clinical research settings of surgical implant patients. The
current study encourages further research exploring the role of MSC in
bone and implant healing with focused targets.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bonr.2016.05.005.
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